Penumbra (NYSE:PEN) updated its FY 2021 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of – for the period. The company issued revenue guidance of $695 million-$705 million, compared to the consensus revenue estimate of $681.51 million.
A number of research analysts recently weighed in on PEN shares. Canaccord Genuity lifted their target price on Penumbra from $204.00 to $310.00 and gave the company a buy rating in a report on Wednesday, February 24th. Citigroup lifted their price objective on Penumbra from $255.00 to $325.00 and gave the company a buy rating in a research note on Tuesday, March 2nd. Wells Fargo & Company increased their target price on shares of Penumbra from $260.00 to $310.00 and gave the stock an overweight rating in a research report on Tuesday, March 2nd. Finally, Zacks Investment Research cut shares of Penumbra from a strong-buy rating to a hold rating in a research report on Wednesday, April 28th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Penumbra has an average rating of Buy and an average price target of $283.29.
Shares of PEN traded down $9.17 during mid-day trading on Tuesday, reaching $288.93. 263,890 shares of the stock traded hands, compared to its average volume of 406,587. The firm has a market cap of $10.54 billion, a price-to-earnings ratio of -1,070.11 and a beta of 0.43. The stock has a fifty day simple moving average of $280.52 and a 200 day simple moving average of $248.25. Penumbra has a 12-month low of $161.11 and a 12-month high of $314.22. The company has a quick ratio of 3.69, a current ratio of 5.46 and a debt-to-equity ratio of 0.04.
Penumbra, Inc engages in the design, development, manufacture, and marketing of innovative medical devices. It offers thrombectomy, embolization, access, neurosurgical tools, ruby coil system, lantern, penumbra occlusion device (POD) system, packing coil, and indigo systems products. Its target markets include interventional neuroradiologists, neurosurgeons, and interventional neurologists; and interventional radiologists, vascular surgeons, and interventional cardiologists.
Read More: Price Target
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.